Immuneering’s $62 Million Series B Financing

Latham & Watkins LLP represented Immuneering Corporation in the transaction.

Immuneering Corporation has announced the completion of an oversubscribed US$62 million Series B financing led by Cormorant Asset Management, with participation from Surveyor Capital (a Citadel company), Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed by BlackRock, Perceptive Advisors and LYFE Capital. Existing investors and senior management also participated in the financing.

Immuneering is forging a new approach to drug discovery, fueled by bioinformatics and computational biology. For more than a decade Immuneering has helped leading pharmaceutical and biotech companies be faster and more productive by analyzing their data to elucidate mechanisms of action, identify biomarkers of response and find new targets.

Latham & Watkins LLP represented Immuneering Corporation in the transaction with an emerging companies deal team led by Boston partners John Chory (Picture) and Evan Smith, with associates Andres Caicedo and Martha Anderson.

Involved fees earner: Martha Louise Anderson – Latham & Watkins; Andres Caicedo – Latham & Watkins; John Chory – Latham & Watkins; Evan Smith – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Immuneering Corporation;


Author: Ambrogio Visconti